Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00695110 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men
A Phase 2 study, sponsored by Clarus Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00695110 is a Phase 2 study that has completed, run by Clarus Therapeutics. The registered enrollment target is 29 participants.
The verdict
NCT00695110, a Phase 2 study, has completed, sponsored by Clarus Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this pharmacokinetic study is to determine whether oral testosterone (T) ester formulations can be used effectively to treat men with low testosterone.
Interventions
- DRUG Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)
- DRUG Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)
- DRUG Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)
- DRUG Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00695110
The ClinicalTrials.gov registry entry for NCT00695110 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clarus Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Oral testosterone undecanoate (TU) (300 mg T equivalents/dose) is the first listed.
NCT00695110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00695110 about?
NCT00695110 is a clinical study titled "Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men". The purpose of this pharmacokinetic study is to determine whether oral testosterone (T) ester formulations can be used effectively to treat men with low testosterone.
What is the current status of trial NCT00695110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2008-06. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00695110?
The interventions under investigation include: Oral testosterone undecanoate (TU) (300 mg T equivalents/dose) (DRUG), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose) (DRUG), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food) (DRUG), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose) (DRUG).
Who is sponsoring clinical trial NCT00695110?
This trial is sponsored by Clarus Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.